{"id":"W2797309423","doi":"10.1056/nejmoa1802357","title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1853,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; EUSA Pharma; Merck Sharp and Dohme; Eisai; Universiteit van Amsterdam; Incyte; LEO Pharma; Massachusetts Medical Society; Sun Pharma; Regeneron Pharmaceuticals; Syndax Pharmaceuticals; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Medicine; Melanoma; Oncology; Internal medicine; Cancer research; Cancer; Biology; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441593,0.0006861074,0.001806818,0.0002739044,0.0002038232,0.0004943332,0.0004039794,0.0006117101,0.001929872],"category_scores_gemma":[0.001476776,0.0002806869,0.000984657,0.0002041151,0.0004202478,0.0003455417,0.0002844002,0.001459027,0.000302818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005363318,"about_ca_system_score_gemma":0.0009803104,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006645778,"about_ca_topic_score_gemma":0.001173855,"domain_scores_codex":[0.9995974,0.0002380833,0.00003722175,0.00004637781,0.00003456766,0.00004643468],"domain_scores_gemma":[0.9992557,0.0002745898,0.0001771268,0.00003287016,0.00003117247,0.0002285042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.925862,0.007934527,0.001434835,0.0007713746,0.0008105992,0.00008927257,0.00008427809,0.0007665954,0.01055011,0.00006822373,0.0004323099,0.05119593],"study_design_scores_gemma":[0.426096,0.553597,0.0121622,0.000174753,0.001251398,0.0001975541,0.0000535106,0.001685213,0.003221907,0.0002281468,0.001311213,0.00002114859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929844,0.005210684,0.0002690047,0.0001813074,0.000171889,0.0004917994,0.0001225716,0.00002751465,0.0005408292],"genre_scores_gemma":[0.9955837,0.002388197,0.0004291301,0.0002374142,0.0001361998,0.0005457481,0.0001404552,0.000004095637,0.00053504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001929872,"threshold_uncertainty_score":0.007623971,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03049556086374712,"score_gpt":0.3167479901321354,"score_spread":0.2862524292683883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}